Plasma-Based, Tumour-Informed MRD Analysis May Predict Recurrence During Adjuvant Osimertinib and Follow-Up in Resected, EGFR-mutated NSCLC By Ogkologos - April 2, 2025 738 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an exploratory analysis of the ADAURA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR How Exercise Can Help You Cope With the Mental and Emotional... August 18, 2022 Her Cancer Surgery Was Postponed Due To The COVID-19 Pandemic —... July 7, 2020 Alzheimer’s-Linked Protein May Help Melanoma Spread to Brain April 1, 2022 Shannen Doherty Opens Up About Life After Cancer And BH90210 August 16, 2019 Load more HOT NEWS Study presents an AI-guided approach to target cancer antigens Pelabresib Plus Ruxolitinib Improves Signs of Underlying Myelofibrosis Pathobiology and Provides... FDA Approves Second CAR T-Cell Therapy for Lymphoma Bean there done that: Can swapping to pulses be the new...
